8-K: Sage Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results, Highlights ZURZUVAE Growth

Sage Therapeutics announces its Q4 and full-year 2024 financial results, highlighting strong ZURZUVAE growth and a cash runway extending to mid-2027.

Summary

• Sage Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company saw strong growth in ZURZUVAE shipments to women with postpartum depression, with nearly 2,500 shipments in Q4 2024, a 21% increase from Q3.
• ZURZUVAE collaboration revenue was $11.4 million in Q4 2024 and $36.1 million for the full year, representing 50% of Biogen's net revenues.
• Cash, cash equivalents, and marketable securities totaled $504 million as of December 31, 2024, expected to fund operations until mid-2027.
• The company is focused on establishing ZURZUVAE as the standard of care for postpartum depression and anticipates significant topline revenue growth in 2025.
• Sage is continuing to explore targeted work within its NMDA receptor negative allosteric modulator (NAM) platform, focusing on potential treatments for neurodevelopmental disorders, with SAGE-817 and SAGE-039.
• The company is evaluating potential indications for SAGE-324, including seizures in developmental and epileptic encephalopathies (DEEs), and expects to provide an update on next steps in mid-2025.
• Net revenue from sales of ZULRESSO was $0.4 million in the fourth quarter of 2024 and $3.6 million for the year ended December 31, 2024.
• Research and development expenses were $37.0 million in Q4 2024 and $225.9 million for the full year.
• Selling, general, and administrative expenses were $54.0 million in Q4 2024 and $216.4 million for the full year.
• Net loss was $95.8 million for Q4 2024 and $400.7 million for the full year.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is experiencing losses, there is strong growth in ZURZUVAE, a solid cash position, and a clear strategy for future growth. The cost-cutting measures and pipeline prioritization are viewed favorably, but the losses and reliance on a single key product temper the overall outlook.

Positives

• Strong growth in ZURZUVAE shipments and revenue indicates increasing market adoption.
• High coverage rates for ZURZUVAE by commercial and Medicaid plans, with favorable coverage policies from national PBMs, facilitate patient access.
• Strong prescriber trends, particularly among OBGYNs, and high repeat prescription rates suggest positive physician perception and patient adherence.
• The extended cash runway provides financial stability and allows for continued investment in R&D and commercialization efforts.
• Cost savings from the October 2024 reorganization are expected to substantially decrease overall operating expenses in 2025.

Negatives

• Net loss of $95.8 million for Q4 2024 and $400.7 million for the full year indicates ongoing financial challenges.
• Decrease in ZULRESSO net revenue from $2.0 million in Q4 2023 to $0.4 million in Q4 2024, and from $10.5 million in 2023 to $3.6 million in 2024, suggests declining sales.
• Restructuring expenses of $22.5 million in Q4 2024 due to the October 2024 reorganization negatively impacted the net loss.

Risks

• Commercialization efforts for ZURZUVAE may not be successful, and revenue generation may not meet expectations.
• The market for ZURZUVAE may be smaller than anticipated.
• Clinical trials for other product candidates may not meet endpoints, impairing development.
• Unexpected adverse events may negatively impact the development and approval of product candidates.
• Collaborations may not yield expected benefits or revenues.
• The company's cash usage and expenses may be higher than expected, potentially impacting the cash runway.
• The company may not achieve anticipated cost savings from the October 2024 reorganization and pipeline prioritization efforts at the levels we expect.

Future Outlook

Sage anticipates that its existing cash, cash equivalents, and marketable securities, along with anticipated funding from ongoing collaborations and estimated revenues, will support operations to mid-2027, and while ZURZUVAE joint commercialization investment will increase in 2025, the Company anticipates overall operating expenses will substantially decrease in 2025 relative to 2024.

Management Comments

• Barry Greene, Chief Executive Officer, stated that ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and believes it will continue to be instrumental in accelerating progress in maternal mental health.
• In 2025, the company's focus will remain on helping more women with postpartum depression receive treatment with ZURZUVAE, advancing focused R&D efforts, and creating near and long-term value for Sage and its shareholders.

Industry Context

Sage's focus on postpartum depression addresses a significant unmet need in women's health, and the growth of ZURZUVAE suggests a positive reception in the market. The collaboration with Biogen is a key factor in the commercialization of ZURZUVAE. The company's pipeline prioritization and cost-saving measures reflect a strategic shift towards sustainable growth.

Comparison to Industry Standards

• Sage's reliance on collaboration revenue, particularly with Biogen for ZURZUVAE, is a common strategy in the biopharmaceutical industry, similar to partnerships seen between smaller biotech firms and larger pharmaceutical companies to share development and commercialization costs.
• The reported R&D expenses of $225.9 million for the year ended December 31, 2024, are within the range of R&D spending for companies of similar size and focus in the CNS therapeutic area; however, the decrease from $356.2 million in the previous year reflects a strategic shift towards pipeline prioritization and cost management.
• The cash runway extending to mid-2027 provides Sage with a competitive advantage compared to other biotech companies that may face near-term funding challenges, allowing for sustained investment in key programs and commercialization efforts.

Stakeholder Impact

• Shareholders: The extended cash runway and focus on value creation are positive, but ongoing losses and reliance on ZURZUVAE pose risks.
• Employees: The October 2024 reorganization and cost-saving measures may impact job security, but the company's focus on key programs could create new opportunities.
• Customers (Patients): Continued commercialization of ZURZUVAE aims to improve access to treatment for postpartum depression.
• Suppliers: The company's financial stability and ongoing R&D efforts support continued partnerships with suppliers.
• Creditors: The strong cash position reduces credit risk.

Next Steps

• Continue commercialization efforts for ZURZUVAE, focusing on expanding market growth in PPD.
• Advance focused R&D efforts, including the Phase 1 multiple ascending dose (MAD) study for SAGE-319.
• Evaluate potential indications for SAGE-324 and provide an update on next steps in mid-2025.
• Explore targeted work within the NMDA receptor NAM platform with SAGE-817 and SAGE-039.

Key Dates